Indian drugmaker launches Lucentis biosimilar; Celyad raises $100M in IPO;

@FierceMedDev: UPDATED with comments from Cynvenio CEO: Cynvenio Biosystems ropes in $25M for liquid biopsy technology. FierceDiagnostics article | Follow @FierceMedDev

@VarunSaxena2: Biotie nets $56M+ in IPO, fellow Parkinson's player Cynapsus up next, followed by Intec Pharma. More from FierceDrugDelivery | Follow @VarunSaxena2

@EmilyWFierce: ICYMI yesterday: Chinese med tech gets the WHO's OK for circumcision device. Article | Follow @EmilyWFierce

> India's Intas Pharmaceuticals launched the world's first biosimilar of Roche's ($RHHBY) blockbuster Lucentis. News

> Belgian biotech Celyad ($CYAD) raised $100 million in an IPO to support its pipeline of gene therapies. More

Biotech News

@FierceBiotech: ICYMI yesterday: Merck KGaA hustling a promising anti-malaria drug into human studies. Report | Follow @FierceBiotech

@JohnCFierce: $TKMR down 15% on the ebola miss. | Follow @JohnCFierce

@DamianFierce: FierceBiotech Radio releases its first double album. This is our All Eyez on Me. More | Follow @DamianFierce

> Lilly and Teva tout new migraine data amid a crowded race. Story

> Antibiotics biotech Nabriva shoots for a $92M IPO. News

> Tekmira's Ebola drug comes up short in Phase II. Article

Pharma News

@FiercePharma: UPDATED: U.S. court nixes Teva's Copaxone patent--again. Report | Follow @FiercePharma

@CarlyHFierce: ICYMI: Merck inks $5.9M settlement to wrap up AzaSite off-label investigation. Article | Follow @CarlyHFierce

> Amgen's Vectibix hits PhIII survival goal in previously treated mCRC patients. Item

> Teva turns up the heat on Mylan, taking its stake past critical threshold. Story

> Celgene hits speedbump for Otezla in U.K. with NICE rejection. Article

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.